Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Dolutegravir; Emtricitabine/tenofovir disoproxil fumarate
  • Indications Hepatitis B; HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms Alliance
  • Sponsors Gilead Sciences

Most Recent Events

  • 12 Mar 2025 According to a Gilead Sciences media release, the company presented data at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).
  • 12 Mar 2025 Results presented in the Gilead Sciences Media Release.
  • 07 Nov 2024 According to a Gilead Sciences media release,three-year outcomes data from this study will be presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top